A Double‐blind, Randomized, Placebo‐controlled, Phase II Trial of Baricitinib for Systemic Lupus Erythematosus: How to Optimize Lupus Trials to Examine Effects on Cutaneous Lupus Erythematosus
British Journal of Dermatology - United Kingdom
doi 10.1111/bjd.17344
Full Text
Open PDFAbstract
Available in full text
Date
April 26, 2019
Authors
Publisher
Wiley